These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16487618)

  • 21. Disulfiram hepatotoxicity: Report of three cases.
    Celada-Sendino M; Álvarez-Navascués C; Rodríguez M
    Med Clin (Barc); 2022 Feb; 158(3):145-146. PubMed ID: 34052023
    [No Abstract]   [Full Text] [Related]  

  • 22. Disulfiram: cautions on liver function; how to supervise.
    Chick J
    Addiction; 2004 Jan; 99(1):25; author reply 27-8. PubMed ID: 14678056
    [No Abstract]   [Full Text] [Related]  

  • 23. Disulfiram use in patients with abnormal liver function test results.
    Saxon AJ; Sloan KL; Reoux J; Haver VM
    J Clin Psychiatry; 1998 Jun; 59(6):313-6. PubMed ID: 9671344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fulminant hepatitis and fatal toxic epidermal necrolysis (Lyell disease) coincident with clarithromycin administration in an alcoholic patient receiving disulfiram therapy.
    Masiá M; Gutiérrez F; Jimeno A; Navarro A; Borrás J; Matarredona J; Martín-Hidalgo A
    Arch Intern Med; 2002 Feb; 162(4):474-6. PubMed ID: 11863483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital.
    Jose J; Rao PG
    Pharmacol Res; 2006 Sep; 54(3):226-33. PubMed ID: 16781163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of prognostic markers in severe drug-induced liver disease.
    Li B; Wang Z; Fang JJ; Xu CY; Chen WX
    World J Gastroenterol; 2007 Jan; 13(4):628-32. PubMed ID: 17278233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Fulminating hepatitis after treatment with naproxen and/or disulfiram?].
    Bell H; Raknerud N
    Tidsskr Nor Laegeforen; 1991 Jan; 111(3):322-3. PubMed ID: 2000613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatal liver failure due to disulfiram.
    Cereda JM; Bernuau J; Degott C; Rueff B; Benhamou JP
    J Clin Gastroenterol; 1989 Feb; 11(1):98-100. PubMed ID: 2646364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinic-epidemiological significance of drug hepatotoxicity in liver disease consultation].
    Jmelnitzky AC; Guidi M; Bologna A; Viola M; Soccini C; Barbero R; Belloni P; Apraiz M
    Acta Gastroenterol Latinoam; 2000; 30(2):77-84. PubMed ID: 10925723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute liver failure: a message found under the skin.
    Meier M; Woywodt A; Hoeper MM; Schneider A; Manns MP; Strassburg CP
    Postgrad Med J; 2005 Apr; 81(954):269-70. PubMed ID: 15811896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Some adverse effects of disulfiram in the treatment of nickel-allergic patients.
    Kaaber K; Menne T; Veien NK; Baadsgaard O
    Derm Beruf Umwelt; 1987; 35(6):209-11. PubMed ID: 3440439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver-unspecific Naranjo scale precise enough to ascertain causality?
    Teschke R; Schmidt-Taenzer W; Wolff A
    Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):567-82. PubMed ID: 21702069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Anterior myocardial infarction in a chronic alcoholic man on disulfiram therapy: a case report].
    Nucifora G; Cassin M; Brun F; Nicolosi GL
    Ital Heart J Suppl; 2004 Dec; 5(12):900-4. PubMed ID: 15709459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C in alcohol dependence:drinking versus disulfiram.
    Kulig CC; Beresford TP
    J Addict Dis; 2005; 24(2):77-89. PubMed ID: 15784525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice.
    Björnsson E; Davidsdottir L
    J Hepatol; 2009 Mar; 50(3):511-7. PubMed ID: 19155082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fulminant hepatitis associated with disulfiram. Report of a case.
    Schade RR; Gray JA; Dekker A; Varma RR; Shaffer RD; Van Thiel DH
    Arch Intern Med; 1983 Jun; 143(6):1271-3. PubMed ID: 6860059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Psychosis during and after disulfiram use].
    Verbon H; de Jong CA
    Ned Tijdschr Geneeskd; 2002 Mar; 146(12):571-3. PubMed ID: 11938582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary ethylglucuronide assessment in patients treated with disulfiram: a tool to improve verification of abstention and safety.
    Mutschler J; Grosshans M; Koopmann A; Mann K; Kiefer F; Hermann D
    Clin Neuropharmacol; 2010; 33(6):285-7. PubMed ID: 20975547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disulfiram-induced neuropathy: a case report.
    Mohapatra S; Sahoo MR; Rath N
    Gen Hosp Psychiatry; 2015; 37(1):97.e5-6. PubMed ID: 25445071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disulfiram-induced hepatitis: case report and review of the literature.
    Mason NA
    DICP; 1989 Nov; 23(11):872-5. PubMed ID: 2688328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.